Greenspring Advisors LLC Lowers Stock Holdings in Danaher Co. (NYSE:DHR)

Greenspring Advisors LLC lowered its stake in Danaher Co. (NYSE:DHR) by 13.2% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,155 shares of the conglomerate’s stock after selling 176 shares during the period. Greenspring Advisors LLC’s holdings in Danaher were worth $265,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Wedge Capital Management L L P NC boosted its position in shares of Danaher by 3.2% in the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 38 shares in the last quarter. Meridian Financial Partners LLC raised its position in shares of Danaher by 4.4% in the 3rd quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock valued at $266,000 after purchasing an additional 40 shares during the last quarter. Kovack Advisors Inc. boosted its stake in Danaher by 3.4% in the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after purchasing an additional 41 shares in the last quarter. Well Done LLC grew its position in Danaher by 1.2% during the 3rd quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock worth $987,000 after purchasing an additional 42 shares during the last quarter. Finally, Waypoint Capital Advisors LLC increased its stake in Danaher by 0.9% during the 3rd quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock valued at $1,257,000 after purchasing an additional 42 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In other news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 10.90% of the company’s stock.

Danaher Trading Down 1.4 %

NYSE:DHR opened at $211.92 on Thursday. Danaher Co. has a 52 week low of $210.04 and a 52 week high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The company has a market cap of $153.07 billion, a PE ratio of 40.14, a P/E/G ratio of 2.80 and a beta of 0.83. The business’s 50 day moving average is $233.96 and its two-hundred day moving average is $252.39.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period last year, the firm posted $2.09 earnings per share. On average, analysts predict that Danaher Co. will post 7.77 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.51%. The ex-dividend date was Friday, December 27th. Danaher’s dividend payout ratio is currently 20.45%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on DHR. UBS Group reduced their target price on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Royal Bank of Canada reiterated an “outperform” rating and set a $277.00 price objective (down from $299.00) on shares of Danaher in a research note on Thursday, January 30th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Stifel Nicolaus boosted their price target on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Finally, Robert W. Baird decreased their price objective on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average target price of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.